Ott de Bruin, L.M.; Pico-Knijnenburg, I.; van Ostaijen-ten Dam, M.M.; Weitering, T.J.; Berghuis, D.; Bredius, R.G.M.; Lankester, A.C.; van der Burg, M.
Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect. Int. J. Mol. Sci. 2023, 24, 16012.
https://doi.org/10.3390/ijms242116012
AMA Style
Ott de Bruin LM, Pico-Knijnenburg I, van Ostaijen-ten Dam MM, Weitering TJ, Berghuis D, Bredius RGM, Lankester AC, van der Burg M.
Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect. International Journal of Molecular Sciences. 2023; 24(21):16012.
https://doi.org/10.3390/ijms242116012
Chicago/Turabian Style
Ott de Bruin, Lisa M., Ingrid Pico-Knijnenburg, Monique M. van Ostaijen-ten Dam, Thomas J. Weitering, Dagmar Berghuis, Robbert G. M. Bredius, Arjan C. Lankester, and Mirjam van der Burg.
2023. "Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect" International Journal of Molecular Sciences 24, no. 21: 16012.
https://doi.org/10.3390/ijms242116012
APA Style
Ott de Bruin, L. M., Pico-Knijnenburg, I., van Ostaijen-ten Dam, M. M., Weitering, T. J., Berghuis, D., Bredius, R. G. M., Lankester, A. C., & van der Burg, M.
(2023). Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell Defect. International Journal of Molecular Sciences, 24(21), 16012.
https://doi.org/10.3390/ijms242116012